NDC 68788-7778-03 - Preferred Maximum Strength Urinary Pain Relief
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68788-7778
- Requested NDC
- 68788-7778-03
- Package NDCs from labels
- 68788-7778-3, 68788-7778-1, 68788-7778-03
- Manufacturer
- Preferred Pharmaceuticals Inc.
- Effective date
- 2026-06-04
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| DRUG FACTS | Preferred Pharmaceuticals Inc. | 2026-06-04 | HUMAN OTC DRUG LABEL |
| DRUG FACTS | Preferred Pharmaceuticals Inc. | 2024-07-02 | HUMAN OTC DRUG LABEL |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | REMEDYREPACK INC. | 49baf6e5-133a-4e1a-9740-506673d27caf | 2026-08-21 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | Preferred Pharmaceuticals Inc. | c0e5d32e-075f-4c76-8332-a06560001efe | 2026-08-14 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | Preferred Pharmaceuticals Inc. | 132cc592-6b03-4b75-bf39-df476fb9dc81 | 2026-08-14 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc | 96308f8c-66e7-486a-a5c0-ee9a133ad051 | 2026-08-14 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | ce702be2-eec2-4346-965e-f1f6ba342fc9 | 2026-08-14 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | REMEDYREPACK INC. | f6829698-b12e-484d-a322-d2f68586e637 | 2026-08-07 | Adverse reactions | 0EWG668W17 |
| Gencare-Urinary Pain Relief Maximum Strength | PHENAZOPYRIDINE HYDROCHLORIDE | Pioneer Life Sciences, LLC | 6bbf15b4-2954-40ff-8460-1ef0ed890654 | 2026-08-03 | Warnings | 1094147 0EWG668W17 |
| Nuvicare-Urinary Pain Relief Maximum Strength | PHENAZOPYRIDINE HYDROCHLORIDE | NUVICARE LLC | 5fe4e4dc-f1c4-4617-b6a6-6ea16a63abfe | 2026-08-03 | Warnings | 1094147 0EWG668W17 |
| Cystex Max Strength UTI Pain Relief | CYSTEX MAX STRENGTH UTI PAIN RELIEF | Clarion Brands LLC | 57482f71-80d3-b20d-e063-6394a90a0cf4 | 2026-07-27 | Warnings | 1094147 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | REMEDYREPACK INC. | 6eb59b69-4ad0-47b1-bd3c-1d04d0852ec5 | 2026-07-27 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | NuCare Pharmaceuticals, Inc. | 56ad921f-0b6e-aa2b-e063-6394a90aec6b | 2026-07-15 | Warnings, Adverse reactions | 0EWG668W17 |
| PHENAZOPYRIDINE HYDROCHLORIDE | PHENAZOPYRIDINE HYDROCHLORIDE | Genus Lifesciences Inc. | 991b3b97-9cea-4c48-90a4-ebff55417d98 | 2026-07-14 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | REMEDYREPACK INC. | 7e131f69-d259-404d-a859-0497f5cbe856 | 2026-06-24 | Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | NuCare Pharmaceuticals, Inc. | 548edf26-c81e-f982-e063-6394a90af9da | 2026-06-18 | Warnings, Adverse reactions | 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE | REMEDYREPACK INC. | 82dc87bb-ba27-4b86-9bc9-18492975ac9f | 2026-06-10 | Adverse reactions | 0EWG668W17 |
| Preferred Maximum Strength Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | 0fa8638c-e3e0-4bbf-9101-842e5d8736d6 | 2026-06-04 | Warnings | 68788-7778-3 68788-7778 68788777803 1094147 0fa8638c-e3e0-4bbf-9101-842e5d8736d6 0fa8638c-e3e0-4bbf-9101-842e5d8736d6 0EWG668W17 |
| Phenazopyridine Hydrochloride | PHENAZOPYRIDINE HYDROCHLORIDE | GPT Pharmaceuticals Private Limited | 7332cbf1-ceda-415b-b4d5-a100057a7d01 | 2026-05-12 | Warnings | 1094147 0EWG668W17 |
| UTI EMERGENCY RELIEF | METHENAMINE, SODIUM SALICYLATE, AND PHENAZOPYRIDINE HYDROCHLORIDE KIT | CADENCE HEALTH, INC. | 3a923df5-15ed-404d-8741-33a9793cb7f5 | 2026-04-06 | Warnings | 1094147 |
| UTI PAIN RELIEF | PHENAZOPYRIDINE HYDROCHLORIDE | Cadence Health | 7fa8e314-025c-46c2-b97a-91c4f385e565 | 2026-04-06 | Warnings | 1094147 0EWG668W17 |
| Urinary Pain Relief | PHENAZOPYRIDINE HYDROCHLORIDE | YYBA CORP | f2d9f6aa-081e-4723-9417-5191b31d2952 | 2026-04-01 | Warnings | 1094147 0EWG668W17 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.